Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM0SRAN)

Drug Name

CC-122 Drug Info

Synonyms

cc-122; 1015474-32-4; Avadomide; 3-(5-Amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione; CC122; CC 122; 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione; 2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-;2,6-Piperidinedione, 3-(5-amino-2-methyl-4-oxo-3(4H)-quinazolinyl)-; Avadomide [USAN]; Avadomide(CC-122); Avadomide (USAN/INN); SCHEMBL282749; US9694015, Compound A; CHEMBL3989934; BDBM76986; RSNPAKAFCAAMBH-UHFFFAOYSA-N; EX-A1191; BCP15938; s7892; AKOS025399378; SB18829; CS-5995

Indication

Disease Entry	ICD 11	Status	REF
Chronic lymphocytic leukaemia	2A82.0	Phase 1	[1]
Diffuse large B-cell lymphoma	2A81	Phase 1	[1]
Hepatocellular carcinoma	2C12.02	Phase 1	[1]
Lymphoma	2A80-2A86	Phase 1	[1]
Multiple myeloma	2A83	Phase 1	[1]
Recurrent glioblastoma	2A00.00	Phase 1	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]

Cross-matching ID

PubChem CID: 24967599
CAS Number: CAS 1015474-32-4
TTD Drug ID: DM0SRAN

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Protein cereblon (CRBN)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CC-220	DMNE7L3	Sarcoidosis	4B20.5	Phase 2	[1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Protein cereblon (CRBN)	TTDKGTC	CRBN_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	ClinicalTrials.gov (NCT01421524) Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma. U.S. National Institutes of Health.